BiotechTube

Inebilizumab

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica Spectrum Disorder

Conditions

Neuromyelitis Optica Spectrum Disorder

Trial Timeline

Jul 3, 2023 → Apr 13, 2027

NCT ID
NCT05549258

About Inebilizumab

Inebilizumab is a phase 2 stage product being developed by Amgen for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05549258. Target conditions include Neuromyelitis Optica Spectrum Disorder.

What happened to similar drugs?

2 of 6 similar drugs in Neuromyelitis Optica Spectrum Disorder were approved

Approved (2) Terminated (1) Active (4)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
✅InebilizumabAmgenApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
🔄SatralizumabRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT06987539Phase 2Recruiting
NCT07222553Phase 2Recruiting
NCT06180278ApprovedActive
NCT05549258Phase 2Recruiting
NCT04540497Phase 3Active

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
SatralizumabRochePhase 3
47
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenApproved
47
intravenous methylprednisoloneBrain BiotechPre-clinical
23